4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) and Axcella Health (NASDAQ:AXLA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Institutional and Insider Ownership 76.6% of 4D Molecular […]
Axcella Health (NASDAQ:AXLA – Get Rating) and Moderna (NASDAQ:MRNA – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Insider and Institutional Ownership 61.8% of Axcella Health shares are owned […]
Axcella Health (NASDAQ:AXLA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The brokerage currently has a $2.75 price target on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 5.77% from […]
Axcella Health Inc. (NASDAQ:AXLA – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2022 earnings estimates for Axcella Health in a research report issued on Wednesday, March 30th. SVB Leerink analyst T. Smith anticipates that the company will post earnings of ($0.42) per share for the quarter. SVB Leerink currently has […]
Zacks Investment Research cut shares of Axcella Health (NASDAQ:AXLA – Get Rating) from a buy rating to a hold rating in a research note released on Tuesday morning, Zacks.com reports. According to Zacks, “Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health […]